67 related articles for article (PubMed ID: 23665979)
41. Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy.
Song JH; Byeon SH; Lee SC; Koh HJ; Kwon OW
Ophthalmologica; 2009; 223(2):85-92. PubMed ID: 19023226
[TBL] [Abstract][Full Text] [Related]
42. Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy.
Reche-Frutos J; Calvo-Gonzalez C; Donate-Lopez J; Garcia-Feijoo J; Leila M; Garcia-Sanchez J
Eur J Ophthalmol; 2008; 18(4):645-8. PubMed ID: 18609492
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathologic findings in polypoidal choroidal vasculopathy.
Nakashizuka H; Mitsumata M; Okisaka S; Shimada H; Kawamura A; Mori R; Yuzawa M
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4729-37. PubMed ID: 18586873
[TBL] [Abstract][Full Text] [Related]
44. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.
Akaza E; Mori R; Yuzawa M
Retina; 2008 May; 28(5):717-22. PubMed ID: 18463515
[TBL] [Abstract][Full Text] [Related]
45. Guidelines for PDT in Japan.
Tano Y;
Ophthalmology; 2008 Mar; 115(3):585-585.e6. PubMed ID: 18319105
[No Abstract] [Full Text] [Related]
46. Role of photodynamic therapy in polypoidal choroidal vasculopathy.
Akaza E; Yuzawa M; Matsumoto Y; Kashiwakura S; Fujita K; Mori R
Jpn J Ophthalmol; 2007; 51(4):270-7. PubMed ID: 17660987
[TBL] [Abstract][Full Text] [Related]
47. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.
Gomi F; Ohji M; Sayanagi K; Sawa M; Sakaguchi H; Oshima Y; Ikuno Y; Tano Y
Ophthalmology; 2008 Jan; 115(1):141-6. PubMed ID: 17582498
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Sakaguchi H; Tsujikawa M; Oshima Y; Kamei M; Tano Y
Br J Ophthalmol; 2008 Jan; 92(1):70-3. PubMed ID: 17567661
[TBL] [Abstract][Full Text] [Related]
49. The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy.
Ghajarnia M; Kurup S; Eller A
Semin Ophthalmol; 2007; 22(2):127-31. PubMed ID: 17564935
[TBL] [Abstract][Full Text] [Related]
50. Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin.
Sayanagi K; Gomi F; Sawa M; Ohji M; Tano Y
Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1569-71. PubMed ID: 17437122
[TBL] [Abstract][Full Text] [Related]
51. Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.
Mauget-Faÿsse M; Quaranta-El Maftouhi M; De La Marnièrre E; Leys A
Eur J Ophthalmol; 2006; 16(5):695-704. PubMed ID: 17061220
[TBL] [Abstract][Full Text] [Related]
52. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
[TBL] [Abstract][Full Text] [Related]
53. Ranibizumab for neovascular age-related macular degeneration.
Rosenfeld PJ; Brown DM; Heier JS; Boyer DS; Kaiser PK; Chung CY; Kim RY;
N Engl J Med; 2006 Oct; 355(14):1419-31. PubMed ID: 17021318
[TBL] [Abstract][Full Text] [Related]
54. Role of photodynamic therapy in polypoidal choroidal vasculopathy.
Hussain N; Hussain A; Natarajan S
Indian J Ophthalmol; 2005 Jun; 53(2):101-4. PubMed ID: 15976464
[TBL] [Abstract][Full Text] [Related]
55. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.
Silva RM; Figueira J; Cachulo ML; Duarte L; Faria de Abreu JR; Cunha-Vaz JG
Graefes Arch Clin Exp Ophthalmol; 2005 Oct; 243(10):973-9. PubMed ID: 15864616
[TBL] [Abstract][Full Text] [Related]
56. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
[TBL] [Abstract][Full Text] [Related]
57. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy.
Matsuoka M; Ogata N; Otsuji T; Nishimura T; Takahashi K; Matsumura M
Br J Ophthalmol; 2004 Jun; 88(6):809-15. PubMed ID: 15148217
[TBL] [Abstract][Full Text] [Related]
58. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula.
Lee SC; Seong YS; Kim SS; Koh HJ; Kwon OW
Ophthalmologica; 2004; 218(3):193-201. PubMed ID: 15103216
[TBL] [Abstract][Full Text] [Related]
59. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy.
Spaide RF; Donsoff I; Lam DL; Yannuzzi LA; Jampol LM; Slakter J; Sorenson J; Freund KB
Retina; 2002 Oct; 22(5):529-35. PubMed ID: 12441716
[TBL] [Abstract][Full Text] [Related]
60. Polypoidal choroidal vasculopathy: natural history.
Uyama M; Wada M; Nagai Y; Matsubara T; Matsunaga H; Fukushima I; Takahashi K; Matsumura M
Am J Ophthalmol; 2002 May; 133(5):639-48. PubMed ID: 11992861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
